-
Tytuł:
-
Hemodynamic Changes During Neuromuscular Electrical Stimulation and Mobility Therapy for an Advanced Heart Failure Patient with Impella 5.0 Device.
-
Autorzy:
-
Nozaki K; Department of Rehabilitation, Kitasato University Hospital.
Hamazaki N; Department of Rehabilitation, Kitasato University Hospital.
Ikeda Y; Department of Cardiovascular Medicine, Kitasato University School of Medicine.
Nihei M; Department of Rehabilitation, Kitasato University Hospital.
Kobayashi S; Department of Rehabilitation, Kitasato University Hospital.
Kamiya K; Department of Rehabilitation, School of Allied Health Sciences, Kitasato University.
Maekawa E; Department of Cardiovascular Medicine, Kitasato University School of Medicine.
Matsunaga A; Department of Rehabilitation, School of Allied Health Sciences, Kitasato University.
Yamaoka-Tojo M; Department of Rehabilitation, School of Allied Health Sciences, Kitasato University.
Ako J; Department of Cardiovascular Medicine, Kitasato University School of Medicine.
-
Źródło:
-
International heart journal [Int Heart J] 2021 May 29; Vol. 62 (3), pp. 695-699. Date of Electronic Publication: 2021 May 15.
-
Typ publikacji:
-
Case Reports; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Tokyo, Japan] : International Heart Journal Association, [2005]-
-
MeSH Terms:
-
Early Ambulation*
Electric Stimulation Therapy*
Heart-Assist Devices*
Heart Failure/*therapy
Shock, Cardiogenic/*therapy
Adult ; Cardiomyopathy, Dilated ; Heart Failure/complications ; Humans ; Male ; Shock, Cardiogenic/complications
-
Contributed Indexing:
-
Keywords: Cardiogenic shock; Early mobilization; Feasibility; Intensive care; Safety
-
Entry Date(s):
-
Date Created: 20210517 Date Completed: 20210610 Latest Revision: 20210610
-
Update Code:
-
20240105
-
DOI:
-
10.1536/ihj.20-632
-
PMID:
-
33994510
-
The Impella 5.0 is a catheter-mounted left ventricular assist device that is inserted through the patient's subclavian artery. This device allows patient mobilization. Early mobility improves outcomes, including physical function and exercise tolerance, in critically ill patients and those with heart failure (HF). However, there have been no studies regarding the safety of early mobilization during the period of Impella 5.0 insertion based on hemodynamic assessment.A 39-year-old man with idiopathic dilated cardiomyopathy and cardiogenic shock was transferred to our hospital for Impella 5.0 insertion. We started neuromuscular electrical stimulation (NMES) and mobilization eight days after Impella 5.0 insertion. The safety of NMES and mobilization was assessed based on mean blood pressure, heart rate (HR), and mean pulmonary artery pressure measurements as hemodynamic indicators. Muscle strength was also assessed using the Medical Research Council (MRC) scale. Throughout the interventions, only the HR increased slightly during mobilization, and there were no hemodynamic abnormalities. Also, the MRC scale score improved as mobilization progressed. The results presented here suggest that NMES and mobilization are safe and feasible in patients with Impella 5.0 insertion, and therefore should be widely adopted.